Publications by authors named "Sen-Han Yang"
Article Synopsis
- CAR-T therapy is effective for B-cell lymphoma but is costly and has safety concerns due to its complicated genetic modification process.
- A new approach, antibody-cell conjugation (ACC), allows for attaching cancer-targeting antibodies to immune cells without genetic changes, resulting in a treatment called ACE1831, which uses rituximab-conjugated γδ2 T cells.
- ACE1831 showed enhanced cancer-killing ability in lab studies and improved survival in mice with B-cell lymphoma, showing promise as an accessible treatment option without harmful side effects.
Natural killer (NK) cells harbor efficient cytotoxicity against tumor cells without causing life-threatening cytokine release syndrome (CRS) or graft-versus-host disease (GvHD). When compared to chimeric antigen receptor (CAR) technology, Antibody-Cell Conjugation (ACC) technology has been developed to provide an efficient platform to arm immune cells with cancer-targeting antibodies to recognize and attack cancer cells. Recently, we established an endogenous CD16-expressing oNK cell line (oNK) with a favorable expression pattern of NK activation/inhibitory receptors.
View Article and Find Full Text PDF